Phase I clinical trial of HLA-A*2402 restricted epitope peptide cocktail therapy with S-1 for patients with unresectable advanced metastatic pancreatic cancer.

Phase I clinical trial of HLA-A*2402 restricted epitope peptide cocktail therapy with S-1 for patients with unresectable advanced metastatic pancreatic cancer. - Phase I clinical trial of HLA-A*2402 restricted epitope peptide cocktail therapy with S-1 for patients with unresectable advanced metastatic pancreatic cancer.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009881

Enrollment

Registered

2013-01-28

Start date

2010-07-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

vaccination using 3 epitope peptides restricted to HLA-A*2402 with S-1 chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who have unresectable advanced pancreatic cancer 2)The presence or absence of measurable or evaluable lesions by RECIST was not taken into account. 3)Performance status (ECOG) of the patients are 0-2. 4)more than 20, less than 80 years of age. 5)Patients who can expect the survival of three months or more. 6)Patients who have undergone operation, and recovered the influence by surgery. Or two weeks or more have passed since pre-medical treatment. 7)Patients who have not been treated with S-1. 8)Adequate food intake 9)without dysfunction of multiple major organs 10)with HLA-A*2402 11)All patients gave written informed consent.

Exclusion criteria

Exclusion criteria: 1)Pregnancy or lactation 2)Patients with the intention of pregnancy. 3)Patients have uncontrollable severe infectional diseases. 4)severe diarrhea. 5)Patients who are treated with steroid or immunotherapy during clinical trial. 6)Patients have uncontrollable multiple cancer. 7)Patients who have non-recovered injury. 8)Patients who have ileus and interstitial lung disiease. 9)Patients whom doctors define as inappropriate.

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Immunological response, Time to progression, Overall survival	—

Countries

Japan

Contacts

Public ContactMasayo Hosokawa

Sapporo Medical University 1st Department of Internal Medicene

hmasayo@sapmed.ac.jp011-611-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026